As part of our commitment to our patients, Chicago ENT’s research team is always conducting research and is frequently involved in clinical trials. Our physicians are thus integral in developing the most cutting-edge, effective treatments available. In addition, it enables Chicago ENT to live up to its name as an Advanced Center for Specialty Care, providing our patients with a host of alternative treatment options. To inquire about our ongoing research and clinical trials, please call (773) 296-5500.
Current: A Prospective, Open-label, Multi-center, Non-inferiority Study Comparing VivAer® to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients with Nasal Valve Dysfunction (The CompAer Study)
New Study Physicians: Dr Friedman and Dr T.K.
Site: Chicago ENT Halsted location.
Rx: Nasal Airway obstruction Treatment study.
Sponsor: Aerin Medical.
Resource website: https://vivaer.com/
Clinical trials Gov link : https://clinicaltrials.gov/study/NCT06922955?cond=vivaer&rank=7
NCT #06922955
Eligibility: Participants will be:
1. Age 22 to 85 years old (inclusively)
2. Willing and able to provide consent
3. Willing and able to comply with the patient-specific requirements outlined in the study protocol
4. Has access to a mobile device, tablet, or computer with internet access and has access to an email address
5. Seeking treatment for NAO
6. Has a NOSE Score of ≥55 indicating severe to extreme NAO
7. Have positive modified Cottle maneuver
8. Planning to undergo an intervention for NAO that includes one of the following as the primary approach:
a. VivAer procedure for repair of nasal valve dysfunction (may include inferior turbinate and septal swell body as additional treated areas)
b. Functional rhinoplasty surgery addressing the nasal valve and/or lateral nasal wall (may be combined with septoplasty with/without turbinoplasty) performed alone or in combination).
c. Septoplasty surgery with turbinate reduction.
To receive more information about this study, or if you know someone who might qualify, contact: Arsalan Aftab [email protected]
Current: For The Treatment of Uncontrolled Asthma in Adolescence (12 and Up) and Adults
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS) – Not Enrolling New Patients
Current: For The Continued Treatment or Chronic Rhinosinusitis and Nasal Polyps in Adults Following Nasal Polyps Surgery
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Removal in Patients with Chronic Rhinosinusitis with Nasal Polyps (OXALIS) – Not Enrolling New Patients
Current: OTO-313-201: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of OTO-313 Given As A Single Intratympanic Injection In Subjects With Unilateral Subjective Tinnitus – Not Enrolling New Patients
Current: Clinical Trial for Nasal Polyps (OPN-3103) in Adolescents 12 to 17 years at 3000 N. Halsted Office – Not Enrolling New Patients
